Ganciclovir Triphosphate
Description
Ganciclovir is a synthetic acyclic-DNA guanine derivative, where the C2' carbon bond is absent. Ganciclovir Triphosphate (ganciclovir-TP, GCV-TP), the active metabolite of ganciclovir, is thought to disrupt viral DNA synthesis by competitive inhibition of viral DNA polymerases and by incorporation into viral DNA, to result in eventual termination of viral DNA elongation. Ganciclovir was first published as 2'-Nor-2'-deoxyguanosine (2'NDG), with noted effectiveness in treating acute herpes simplex infections in mice. Recently it has been studied as an Epstein-Barr Virus treatment, as well as a prostate cancer, human cytomegalovirus (HCMV) retinitis and CMV antigeemia preemptive treatment. The triphosphorylated form (GCV-TP) is an important control in this research.
Product details
| Catalog No | N-9001 |
| Purity | ≥95% by AX-HPLC |
| Extinction Coefficient | 13 |
| Molecular Formula | C₉H₁₆N₅O₁₃P₃ (free acid) |
| Molecular Weight | 495.20 g/mole (free acid) |
| Salt Form | Li+ |
| Concentration | 100 mM |
| Buffer | H₂O |
| Recommended Storage | -20°C or below |
| Application | Aptamers |
| Backbone | 5'-Triphosphate |
| Base Analog(s) | Guanosine |
| Nucleotide Category | Non-nucleotide |
| Shipping Temp | Frozen |
| Sugars | RNA |
Technical documents
- Safety Data Sheet Look-up open_in_new
Certificate of analysis
- Certificate of Analysis (CoA) open_in_new
Intellectual property
Products are for research use only, not for use in diagnostic or therapeutic procedures or for use in humans. Products are not for resale without express written permission from TriLink No license under any patent or other intellectual property right of TriLink or its licensors is granted or implied by the purchase unless otherwise provided in writing.